Ignite Creation Date:
2024-05-05 @ 8:01 PM
Last Modification Date:
2024-10-26 @ 9:57 AM
Study NCT ID:
NCT00780728
Status:
WITHDRAWN
Last Update Posted:
2009-11-13
First Post:
2008-10-27
Brief Title:
Study Evaluating the Addition of Sildenafil to Bosentan Therapy in Pulmonary Arterial Hypertension
Sponsor:
University Health Network Toronto
Organization:
University Health Network Toronto
Study Overview
Official Title:
Addition of Sildenafil to Bosentan Monotherapy in Patients With Pulmonary Arterial Hypertension PAH
Status:
WITHDRAWN
Status Verified Date:
2009-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will examine the effects of add-on sildenafil to bosentan monotherapy in patients with Pulmonary Arterial Hypertension Patients on bosentan monotherapy will be followed every 6 months to assess if they have met the pre-defined treatment goals If a patient fails to achieve these treatment goals or fails to maintain them sildenafil will be added to their existing bosentan monotherapy Patients will be assessed 6 months after start of combination therapy for changes in 6MWT Borg dyspnea scale WHO functional class quality of life
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None